Literature DB >> 19015632

Treatment target in schizophrenia: a critical review and a clinical suggestion.

Takefumi Suzuki1, Hiroyuki Uchida, Koichiro Watanabe, Haruo Kashima.   

Abstract

BACKGROUND: Patients with schizophrenia have many problems as well as symptoms, and various rating scales have been in use to address them.
METHOD: The authors review past representative rating scales and some pivotal studies to focus on treatment target in schizophrenia.
RESULTS: Traditionally, positive symptoms have been the main target of treatment. However, other crucial domains such as negative and cognitive symptoms, and subjective perspectives are drawing due attention because of their clinical relevance. Given many domains to be addressed, there have eventually been too many assessment scales to be selected and widely utilized in real-world clinical settings, and there has been still no concrete consensus on which scales to utilize in a given situation, which is currently decided at the discretion of the investigators. Measurement is frequently difficult even with the existing assessments, especially as what constitutes an acceptable clinical status is hard to define, considering highly hetero generous nature of the illness. Many rating scales are met with limitations especially in time and in pragmatic comprehensiveness, which often hinder their routine application in time-limited busy settings. Still, problems and functioning of patients are the reasonable target to evaluate for measurement-based treatment.
CONCLUSIONS: The authors suggest assessment of problems resulting from symptoms together with objective functioning, which clinical psychiatrists are actually doing in everyday practice, would serve as a minimum set of standardized assessment in schizophrenia, and the newly developed TIP-Sz and FACT-Sz would serve for that purpose. Other crucial viewpoints could be supplemented with (subjective) assessment scales as appropriate.

Entities:  

Mesh:

Year:  2008        PMID: 19015632

Source DB:  PubMed          Journal:  Psychopharmacol Bull        ISSN: 0048-5764


  6 in total

1.  Subtyping Schizophrenia by Social Functioning - a Pragmatic Proposal for Clinics and Research.

Authors:  Takefumi Suzuki
Journal:  Psychiatr Q       Date:  2018-09

Review 2.  Management of schizophrenia in late life with antipsychotic medications: a qualitative review.

Authors:  Takefumi Suzuki; Gary Remington; Hiroyuki Uchida; Tarek K Rajji; Ariel Graff-Guerrero; David C Mamo
Journal:  Drugs Aging       Date:  2011-12-01       Impact factor: 3.923

Review 3.  Which rating scales are regarded as 'the standard' in clinical trials for schizophrenia? A critical review.

Authors:  Takefumi Suzuki
Journal:  Psychopharmacol Bull       Date:  2011

4.  A Chinese version of the Psychotic Symptom Rating Scales: psychometric properties in recent-onset and chronic psychosis.

Authors:  Wai-Tong Chien; Isabella Yuet-Ming Lee; Li-Qun Wang
Journal:  Neuropsychiatr Dis Treat       Date:  2017-03-08       Impact factor: 2.570

5.  The Use of the Japanese Public Financial Support Has Positive Impact on Persistence with Outpatient Treatments for Schizophrenia: Single-center Retrospective Cohort Study in Japan.

Authors:  Masatoshi Arikawa; Kazumi Ota; Takaharu Azekawa; Shizuko Ohashi; Yoichi Funaoka; Hiroshi Yoshiie; Haruka Koshi; Yohei Takaishi; Saeka Nakao
Journal:  Patient Prefer Adherence       Date:  2021-02-02       Impact factor: 2.711

6.  Factors related to improvement of symptoms, function, and caregiver burden in Chinese patients with schizophrenia after switching to paliperidone palmitate once-monthly from oral antipsychotics.

Authors:  Nan Li; Yu Feng; Huafei Lu; Shang Li Cai; Jianmin Zhuo; Tianmei Si; Lili Zhang
Journal:  Neuropsychiatr Dis Treat       Date:  2018-03-22       Impact factor: 2.570

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.